期刊文献+

非小细胞肺癌隐匿性淋巴结转移危险因素分析 被引量:10

Risk factors for occult lymph node metastasis in patients with non-small cell lung cancer
原文传递
导出
摘要 目的隐匿性淋巴结转移(occult lymph node metastasis,OLM)对肺癌临床分期非常重要,如何将OLM低危人群筛查出来,以便外科医生制定合适的治疗方案是目前研究热点。本研究探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者隐匿性淋巴结转移影响因素。方法收集2009-07-15-2016-05-15南京医科大学第一附属医院收治的337例NSCLC患者临床资料,术前PET/CT显像诊断均为临床N0期。通过单因素及多因素分析筛选出隐匿性淋巴结转移的独立危险因素。结果 337例NSCLC患者,术后病理确诊淋巴结转移90例(26.7%,90/337),其中N1淋巴结转移46例,N2淋巴结转移44例。单因素分析结果显示,肿瘤位置、肺膜侵犯、脉管浸润、肿瘤最大径、SUVmax和病灶糖酵解总量(total lesion glycolysis,TLG)为NSCLC隐匿性淋巴结转移的危险因素,均P<0.05。多因素分析结果显示,脉管浸润(OR=3.453,95%CI=1.321~9.082,P=0.011)、肿瘤最大径(OR=1.850,95%CI=1.030~13.322,P=0.039)、TLG(OR=3.092,95%CI=1.124~8.510,P=0.029)是隐匿性淋巴结转移的独立危险因素。根据TLG与肿瘤最大径将患者分为低危组(n=125)、中危组(n=106)及高危组(n=106),3组患者隐匿性淋巴结转移的发生率分别为8.8%(11/125)、23.6%(25/106)和50.9%(54/106),差异有统计学意义,χ2=52.815,P<0.001。结论脉管浸润、肿瘤最大径及18F-FDG PET/CT显像所测得的TLG是NSCLC隐匿性淋巴结转移的独立危险因素,18 F-FDG PET/CT显像结果可为外科制定手术方案提供一定的参考价值。 OBJECTIVE Occult lymph node metastasis(OLM) is important for the clinical staging of lung cancer. How to screen OLM patients with low risk so that surgeons can develop appropriate treatment plans is a hot topic of cur rent research. This study aimed to assess risk factors in NSCLC with occult OLM. METHODS Records of 337 patients with N0 stage NSCLC staged by preoperation 18 FFDG PET/CT between July 15th 2009 and May 15th 2016 were retro- spectively reviewed. To identify risk factors for occult lymph node metastasis, univariate and multivariate logistic regres- sion analyses were performed. RESULTS Of 337 patients, 90 (26. 7%,90/337) had OLM conformed by pathology; 46 were N1 and 44 were N2. In univariate analysis, six risk factors were identified: tumor location, pleural invasion, vascular invasion, tumor size, SUVm,x and TLG (all P〈0.05). On multivariate analyses, vascular invasion ( OR = 3.453,95 M CI = 1.321-9.082,P=0. 011),tumor size (OR=1. 850,95%CI=1. 030--13. 322,P=0. 039) and TLG (OR=3. 092, 95MCI=1.124--8.510,P=0. 029) were the independent risk factors for OLM. According the TLG and tumor size,pa tients were divided into three groups:low-risk group(n = 125 ), moderate-risk group (n=106) and high-risk group (n = 106). The OLM rates of the three groups were 8.8%(11/125) ,23.6%(25/106) ,50.9%(54/106) ,respectively,with sig- nificant difference(X^2 =52. 815,P〈0. 001). CONCLUSIONS Vascular invasion, tumor size and TLG measured on 18F-FDC- PET/CT are the independent Dredictive risk factors for OLM. 18 F-FDG PET/CT can be used to guide surgical Dlanning.
作者 黄斌 丁重阳 李天女 HUANG Bin;DING Chong-yang;LI Tian-nv(Department of Oncology,Nanjing Drum Tower Hospital,Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,P.R.China;Department of Nuclear Medicine,First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,P.R.China)
出处 《中华肿瘤防治杂志》 CAS 北大核心 2018年第15期1089-1093,共5页 Chinese Journal of Cancer Prevention and Treatment
基金 2016中央高校基本科研业务费专项资金(021414380147) 南京医科大学"十二五"校级教育研究课题(JYY2015108)
关键词 肺肿瘤 非小细胞 肿瘤转移 淋巴结 脱氧葡萄糖 lung neoplasms non-small cell neoplasms metastasis lymph nodes deoxyglucose
  • 相关文献

参考文献3

二级参考文献43

  • 1吴湖炳,王全师,王明芳,郭晓君,唐刚华.^(18)F-FDGPET显像半定量分析与肺癌病理类型及分期的关系[J].中华核医学杂志,2006,26(1):29-31. 被引量:29
  • 2D'Addario G, Felip E, ESMO Guidelines Working Group. Non- small-cell lung cancer: ESMO clinical recommendations for diagno- sis, treatment and follow-up[J]. Ann Oncol, 2009, 20 Suppl 4: 68-70.
  • 3Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer[ J]. J Natl Compr Canc Netw, 2012, 10: 1236-1271.
  • 4Silvestri GA, Gould MK, Margolis ML, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition)[J]. Chest, 2007,132 (3 Suppl) : 178S- 201S.
  • 5de Langen A J, Raijmakers P, Riphagen I, et al. The size of medi- astinal lymph nodes and its relation with metastatic involvement: a meta-analysis[J]. Eur J Cardiothorac Surg, 2006, 29: 26-29.
  • 6Lee PC, Port JL, Korst RJ, et al. Risk factors for occult mediasti- nal metastases in clinical stage I non-small cell lung cancer[ J]. Ann Thorac Surg, 2007, 84: 177-181.
  • 7Detterbeck FC, Jantz MA, Wallace M, et al. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practiceguidelines (2nd edition)[J]. Chest, 2007, 132(3 Suppl) : 202S- 220S.
  • 8Yang F, Chen H, Xiang J, et al. Relationship between tumor size and disease stage in non-small cell lung cancer[ J]. BMC Cancer, 2010, 10: 474.
  • 9AI-Sarraf N, Aziz R, Gately K, et al. Pattern and predictors of oc- cult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emis- sion tomography[ J]. Eur J Cardiothorac Surg, 2008, 33 : 104-109.
  • 10Cerfolio R J, Bryant AS, Ohja B, et al. The maximum standardized up- take values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival[J]. J Thorac Cardiovasc Surg, 2005, 130: 151-159.

共引文献40

同被引文献56

引证文献10

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部